Arrowhead Pharmaceuticals Stock Price Target and Analyst Ratings (NASDAQ:ARWR)

Analyst Price Target for ARWR

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

^$76.62

▼ -8.18% Downside Potential

This price target is based on 12 analysts offering 12 month price targets for Arrowhead Pharmaceuticals in the last 3 months. The average price target is $76.62, with a high forecast of $98.00 and a low forecast of $34.00. The average price target represents a -8.18% upside from the last price of $83.44.

Buy

The current consensus among 12 contributing investment analysts is to buy stock in Arrowhead Pharmaceuticals. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
6 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

7/30/2019

0 strong buy ratings
4 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

10/28/2019

0 strong buy ratings
6 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

1/26/2020

0 strong buy ratings
6 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

4/25/2020

0 strong buy ratings
7 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

7/24/2020

0 strong buy ratings
8 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

10/22/2020

0 strong buy ratings
9 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

12/21/2020

0 strong buy ratings
9 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

1/20/2021

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price	Details
12/21/2020	Robert W. Baird	Downgrade	Outperform ➝ Neutral	$75.00	High	i
12/15/2020	UBS Group	Initiated Coverage	Buy	$95.00	Low	i
11/24/2020	Royal Bank of Canada	Boost Price Target	Positive ➝ Outperform	$62.00 ➝ $80.00	High	i
11/24/2020	Cantor Fitzgerald	Boost Price Target	Overweight	$58.00 ➝ $80.00	High	i
11/24/2020	SVB Leerink	Lower Price Target	Market Perform	$35.00 ➝ $34.00	High	i
11/19/2020	Smith Barney Citigroup	Initiated Coverage	Buy	$90.00	Low	i
11/19/2020	Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell	Initiated Coverage	Buy	$90.00	Low	i
11/17/2020	B. Riley	Boost Price Target	Buy ➝ Positive	$68.00 ➝ $98.00	Low	i
11/16/2020	Robert W. Baird	Boost Price Target	Outperform	$70.00 ➝ $75.00	Low	i
10/12/2020	B. Riley	Boost Price Target		$57.00 ➝ $68.00	Low	i Rating by Mayank Mamtani at B. Riley
10/12/2020	HC Wainwright	Reiterated Rating	Buy		Low	i Rating by P. Trucchio at HC Wainwright
10/8/2020	Piper Sandler	Boost Price Target		$80.00 ➝ $90.00	High	i
9/17/2020	SVB Leerink	Boost Price Target	Market Perform	$29.00 ➝ $31.00	Low	i Rating by M. Foroohar at SVB Leerink LLC
8/24/2020	HC Wainwright	Reiterated Rating	Buy		Low	i Rating by P. Trucchio at HC Wainwright
7/29/2020	Chardan Capital	Reiterated Rating	Buy	$81.00	High	i Rating by Keay Nakae at Chardan Capital
5/12/2020	Royal Bank of Canada	Initiated Coverage	Outperform	$62.00	High	i
5/10/2020	B. Riley	Reiterated Rating	Buy	$57.00	High	i Rating by Mayank Mamtani at B. Riley
5/8/2020	Cantor Fitzgerald	Reiterated Rating	Buy	$60.00 ➝ $58.00	High	i Rating by A. Young at Cantor Fitzgerald
5/8/2020	Oppenheimer	Upgrade	Market Perform ➝ Outperform	$58.00	High	i Rating by Esther Rajavelu at Oppenheimer Holdings Inc.
4/15/2020	Cantor Fitzgerald	Upgrade	Neutral ➝ Overweight	$55.00 ➝ $60.00	High	i Rating by A. Young at Cantor Fitzgerald
3/31/2020	B. Riley	Reiterated Rating	Buy	$57.00	High	i Rating by Mayank Mamtani at B. Riley
3/24/2020	SVB Leerink	Upgrade	Underperform ➝ Market Perform	$29.00	Medium	i Rating by Mani Foroohar at SVB Leerink LLC
3/17/2020	The Goldman Sachs Group	Initiated Coverage	Neutral	$45.00	Medium	i
3/13/2020	B. Riley	Lower Price Target	Buy	$83.00 ➝ $57.00	High	i Rating by Mayank Mamtani at B. Riley
2/7/2020	Jefferies Financial Group	Boost Price Target		$77.00 ➝ $80.00	Medium	i
2/6/2020	B. Riley	Reiterated Rating	Buy	$83.00	High	i Rating by Mayank Mamtani at B. Riley
2/6/2020	Cantor Fitzgerald	Boost Price Target	Neutral	$50.00 ➝ $55.00	High	i Rating by A. Young at Cantor Fitzgerald
1/24/2020	B. Riley	Reiterated Rating	Buy	$83.00	Low	i Rating by Mayank Mamtani at B. Riley
1/21/2020	SVB Leerink	Initiated Coverage	Underperform	$32.00	High	i Rating by M. Foroohar at SVB Leerink LLC
12/12/2019	Oppenheimer	Initiated Coverage	Hold		Medium	i Rating by Esther Rajavelu at Oppenheimer Holdings Inc.
12/9/2019	Piper Jaffray Companies	Boost Price Target	Overweight	$72.00 ➝ $80.00	Medium	i Rating by Edward Tenthoff at Piper Jaffray Companies
11/29/2019	Chardan Capital	Reiterated Rating	Buy	$45.00 ➝ $81.00	Medium	i
11/27/2019	B. Riley	Reiterated Rating	Buy	$59.00 ➝ $83.00	High	i Rating by Mayank Mamtani at B. Riley
11/26/2019	S&P Equity Research	Reiterated Rating	Buy		Medium	i
11/26/2019	Piper Jaffray Companies	Reiterated Rating	Overweight	$54.00 ➝ $72.00	High	i Rating by Edward Tenthoff at Piper Jaffray Companies
11/25/2019	Robert W. Baird	Upgrade	Neutral ➝ Outperform	$39.00 ➝ $70.00	High	i
11/19/2019	Cantor Fitzgerald	Reiterated Rating	Neutral	$24.00 ➝ $50.00	Medium	i Rating by A. Young at Cantor Fitzgerald
11/13/2019	B. Riley	Boost Price Target	Buy	$46.00 ➝ $59.00	Low	i Rating by Mayank Mamtani at B. Riley
10/24/2019	Robert W. Baird	Downgrade	Outperform ➝ Neutral	$39.00	High	i
10/22/2019	Chardan Capital	Boost Price Target	Buy	$32.00 ➝ $45.00	High	i
10/21/2019	B. Riley	Set Price Target	Buy	$46.00	High	i Rating by Mayank Mamtani at B. Riley
10/20/2019	Piper Jaffray Companies	Boost Price Target	Overweight	$50.00 ➝ $54.00	Low	i
10/17/2019	Cantor Fitzgerald	Reiterated Rating	Neutral		Low	i Rating by A. Young at Cantor Fitzgerald
10/2/2019	Robert W. Baird	Initiated Coverage	Outperform	$39.00	Medium	i
9/16/2019	Piper Jaffray Companies	Reiterated Rating	Overweight	$50.00	Medium	i
8/19/2019	B. Riley	Boost Price Target	Buy	$32.00 ➝ $46.00	High	i Rating by Mayank Mamtani at B. Riley
8/6/2019	Piper Jaffray Companies	Boost Price Target	Overweight	$33.00 ➝ $50.00	Low	i
6/27/2019	Cantor Fitzgerald	Downgrade	Overweight ➝ Neutral	$24.00	High	i Rating by Elemer Piros at Cantor Fitzgerald
5/28/2019	B. Riley	Boost Price Target	Buy	$26.00 ➝ $32.00	Low	i
5/13/2019	B. Riley	Boost Price Target	Buy	$19.00 ➝ $26.00	High	i
4/16/2019	Piper Jaffray Companies	Boost Price Target	Overweight	$25.00 ➝ $33.00	Medium	i
4/12/2019	Cantor Fitzgerald	Set Price Target	Buy	$24.00	Low	i Rating by Elemer Piros at Cantor Fitzgerald
2/11/2019	Chardan Capital	Reiterated Rating	Buy	$24.50	High	i Rating by Keay Nakae at Chardan Capital
12/17/2018	Chardan Capital	Reiterated Rating	Buy	$24.50	Low	i Rating by Keay Nakae at Chardan Capital
12/11/2018	Cantor Fitzgerald	Set Price Target	Buy	$24.00	High	i Rating by Elemer Piros at Cantor Fitzgerald
10/17/2018	William Blair	Reiterated Rating	Outperform		Medium	i
10/14/2018	Chardan Capital	Set Price Target	Buy	$25.00	Low	i Rating by Keay Nakae at Chardan Capital
10/11/2018	Cantor Fitzgerald	Reiterated Rating	Buy	$24.00	Low	i Rating by Justin Kim at Cantor Fitzgerald
10/4/2018	Cantor Fitzgerald	Boost Price Target	Overweight	$18.00 ➝ $24.00	High	i Rating by Elemer Piros at Cantor Fitzgerald
10/4/2018	Piper Jaffray Companies	Reiterated Rating	Overweight	$25.00	High	i
10/2/2018	Cantor Fitzgerald	Set Price Target	Buy	$18.00	High	i Rating by Elemer Piros at Cantor Fitzgerald
9/14/2018	Jefferies Financial Group	Boost Price Target	Positive ➝ Buy	$24.00	Medium	i Rating by Maury Raycroft at Jefferies Financial Group Inc.
9/6/2018	Chardan Capital	Boost Price Target	Buy ➝ Buy	$17.50 ➝ $24.50	Medium	i Rating by Keay Nakae at Chardan Capital
9/6/2018	B. Riley	Upgrade	Neutral ➝ Buy	$18.00 ➝ $19.00	High	i Rating by M. Kumar at B. Riley
9/6/2018	Cantor Fitzgerald	Set Price Target	Buy	$18.00	High	i Rating by Elemer Piros at Cantor Fitzgerald
8/13/2018	Chardan Capital	Reiterated Rating	Buy	$17.50	Medium	i Rating by Keay Nakae at Chardan Capital
8/8/2018	Cantor Fitzgerald	Reiterated Rating	Overweight	$13.00	Medium	i Rating by Elemer Piros at Cantor Fitzgerald
8/8/2018	Jefferies Financial Group	Reiterated Rating	Buy	$20.00	Low	i Rating by Maury Raycroft at Jefferies Financial Group Inc.
8/8/2018	B. Riley	Boost Price Target	Neutral ➝ Neutral	$12.00 ➝ $18.00	High	i
8/7/2018	Cantor Fitzgerald	Set Price Target	Buy	$13.00 ➝ $18.00	High	i Rating by Elemer Piros at Cantor Fitzgerald
8/1/2018	Cantor Fitzgerald	Initiated Coverage	Buy	$13.00	Low	i Rating by Elemer Piros at Cantor Fitzgerald
7/8/2018	Chardan Capital	Set Price Target	Buy	$16.00	High	i Rating by Keay Nakae at Chardan Capital
7/2/2018	Chardan Capital	Boost Price Target	Buy	$9.50 ➝ $16.00	High	i Rating by K. Nakae at Chardan Capital
6/29/2018	Piper Jaffray Companies	Reiterated Rating	Overweight	$17.00	Low	i
6/18/2018	S&P Equity Research	Lower Price Target		$13.76 ➝ $11.68	Medium	i
6/18/2018	Cantor Fitzgerald	Reiterated Rating	Buy	$13.00	High	i Rating by Elemer Piros at Cantor Fitzgerald
5/30/2018	Cantor Fitzgerald	Reiterated Rating	Buy	$13.00	High	i Rating by E. Piros at Cantor Fitzgerald
5/8/2018	Piper Jaffray Companies	Boost Price Target	Overweight	$11.00	High	i
5/8/2018	Cantor Fitzgerald	Upgrade	Neutral ➝ Overweight	$13.00	High	i Rating by Elemer Piros at Cantor Fitzgerald
3/27/2018	Jefferies Financial Group	Initiated Coverage	Buy	$10.00	High	i
2/19/2018	Chardan Capital	Reiterated Rating	Buy	$7.00	Low	i Rating by K. Nakae at Chardan Capital
2/12/2018	B. Riley	Boost Price Target	Neutral ➝ Neutral	$3.00 ➝ $4.00	Medium	i Rating by M. Kumar at B. Riley
2/12/2018	Cantor Fitzgerald	Set Price Target	Neutral ➝ Neutral	$2.00 ➝ $5.00	Medium	i Rating by Elemer Piros at Cantor Fitzgerald
1/16/2018	Chardan Capital	Reiterated Rating	Neutral		Medium	i Rating by K. Nakae at Chardan Capital
1/5/2018	B. Riley	Initiated Coverage	Neutral ➝ Neutral	$3.00	Medium	i Rating by M. Kumar at B. Riley
12/12/2017	Cantor Fitzgerald	Set Price Target	Hold	$2.00	Medium	i Rating by Elemer Piros at Cantor Fitzgerald
11/27/2017	Piper Jaffray Companies	Upgrade	Neutral ➝ Overweight	$5.50	High	i
9/25/2017	Cantor Fitzgerald	Reiterated Rating	Hold	$2.00	Medium	i
9/18/2017	William Blair	Upgrade	Market Perform ➝ Outperform		High	i Rating by Y. Xu at William Blair
9/15/2017	Cantor Fitzgerald	Reiterated Rating	Hold	$1.00 ➝ $2.00	High	i
9/13/2017	Chardan Capital	Reiterated Rating	Neutral		Medium	i Rating by G. Amusa at Chardan Capital
8/4/2017	Jefferies Financial Group	Reiterated Rating	Hold	$2.00	High	i
7/28/2017	Piper Jaffray Companies	Reiterated Rating	Hold	$2.00	Medium	i
4/12/2017	Jefferies Financial Group	Reiterated Rating	Hold	$2.00	Low	i
11/30/2016	Jefferies Financial Group	Reiterated Rating	Hold	$5.00 ➝ $2.00	N/A	i
11/30/2016	William Blair	Downgrade	Outperform ➝ Market Perform	$12.00 ➝ $2.00	N/A	i Rating by Y. Xu at William Blair
11/30/2016	Piper Jaffray Companies	Downgrade	Overweight ➝ Neutral	$10.00 ➝ $2.00	N/A	i
11/30/2016	Cantor Fitzgerald	Downgrade	Buy ➝ Hold	$15.00 ➝ $1.00	N/A	i Rating by elemer piros at Cantor Fitzgerald
11/30/2016	Chardan Capital	Downgrade	Buy ➝ Neutral	$8.00 ➝ $2.00	N/A	i Rating by Madhu Kumar at Chardan Capital
11/10/2016	Cantor Fitzgerald	Reiterated Rating	Buy	$15.00	N/A	i Rating by elemer piros at Cantor Fitzgerald
11/10/2016	Jefferies Financial Group	Lower Price Target	Hold	$6.50 ➝ $5.00	N/A	i
11/10/2016	Chardan Capital	Lower Price Target	Buy	$10.00 ➝ $8.00	N/A	i Rating by Madhu Kumar at Chardan Capital
9/29/2016	Chardan Capital	Set Price Target	Buy	$10.00	N/A	i Rating by Madhu Kumar at Chardan Capital
9/29/2016	Cantor Fitzgerald	Reiterated Rating	Buy	$15.00	N/A	i Rating by elemer piros at Cantor Fitzgerald
9/7/2016	Chardan Capital	Reiterated Rating	Buy	$10.00	N/A	i
8/19/2016	William Blair	Initiated Coverage	Outperform		N/A	i Rating by Y. Xu at William Blair
8/17/2016	Cantor Fitzgerald	Initiated Coverage	Buy	$15.00	N/A	i
8/10/2016	Piper Jaffray Companies	Lower Price Target	Overweight	$13.00 ➝ $8.00	N/A	i
5/19/2016	Chardan Capital	Initiated Coverage	Buy	$12.00	N/A	i Rating by M. Kumar at Chardan Capital
5/11/2016	Jefferies Financial Group	Reiterated Rating	Hold	$4.75	N/A	i
2/11/2016	Piper Jaffray Companies	Reiterated Rating	Overweight	$20.00 ➝ $13.00	N/A	i Rating by Edward Tenthoff at Piper Jaffray Companies
2/10/2016	Jefferies Financial Group	Lower Price Target	Hold	$7.00 ➝ $4.00	N/A	i

(Data available from 1/21/2016 forward)

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in Phase I/II clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase I/II clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Phase I/II clinical trial for treating liver diseases; ARO-ENaC, which is in Phase I/II clinical trial to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; ARO-Lung2 for the treatment of chronic obstructive pulmonary disorder; ARO-COV for the treatment of COVID-19 and other pulmonary-borne pathogens; and ARO-HIF2, which is in phase Ib for the treatment of clear cell renal cell carcinoma. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular target. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate. The company was formerly known as Arrowhead Research Corporation and changed its name to Arrowhead Pharmaceuticals, Inc. in April 2016. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.

Today's Range

Now: $83.44

$82.40

$84.98

50 Day Range

MA: $77.09

$63.98

$85.37

52 Week Range

Now: $83.44

$19.51

$86.75

Volume

656,129 shs

Average Volume

875,402 shs

Market Capitalization

$8.57 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.62

Frequently Asked Questions

What sell-side analysts currently cover shares of Arrowhead Pharmaceuticals?

The following equities research analysts have issued research reports on Arrowhead Pharmaceuticals in the last twelve months: B. Riley, Cantor Fitzgerald, Chardan Capital, Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell, HC Wainwright, Jefferies Financial Group Inc., Oppenheimer Holdings Inc., Piper Sandler, Robert W. Baird, Royal Bank of Canada, Smith Barney Citigroup, SVB Leerink LLC, The Goldman Sachs Group, Inc., TheStreet, and UBS Group AG.

What is the current price target for Arrowhead Pharmaceuticals?

13 Wall Street analysts have set twelve-month price targets for Arrowhead Pharmaceuticals in the last year. Their average twelve-month price target is $76.62, suggesting a possible downside of 6.7%. B. Riley has the highest price target set, predicting ARWR will reach $98.00 in the next twelve months. SVB Leerink LLC has the lowest price target set, forecasting a price of $34.00 for Arrowhead Pharmaceuticals in the next year.

What is the current consensus analyst rating for Arrowhead Pharmaceuticals?

Arrowhead Pharmaceuticals currently has 3 hold ratings and 9 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ARWR will outperform the market and that investors should add to their positions of Arrowhead Pharmaceuticals.

What other companies compete with Arrowhead Pharmaceuticals?

Other companies that are similar to Arrowhead Pharmaceuticals include BeiGene, Astellas Pharma, Genmab A/S, Genmab A/S, Takeda Pharmaceutical, Shiseido, MERCK Kommanditgesellschaft auf Aktien, UCB, Royalty Pharma, Catalent, Alnylam Pharmaceuticals, CureVac, Horizon Therapeutics Public, BioMarin Pharmaceutical and Elanco Animal Health.

How do I contact Arrowhead Pharmaceuticals' investor relations team?

Arrowhead Pharmaceuticals' physical mailing address is 177 E. Colorado Blvd Suite 700, Pasadena CA, 91105. The biotechnology company's listed phone number is 626-304-3400 and its investor relations email address is ir@arrowheadpharma.com. The official website for Arrowhead Pharmaceuticals is www.arrowheadpharma.com.

NASDAQ:ARWR - Arrowhead Pharmaceuticals Stock Price Target and Predictions

Analyst Price Target for ARWR

Past Monthly Recommendations

Latest Recommendations

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Frequently Asked Questions

What sell-side analysts currently cover shares of Arrowhead Pharmaceuticals?

What is the current price target for Arrowhead Pharmaceuticals?

What is the current consensus analyst rating for Arrowhead Pharmaceuticals?

What other companies compete with Arrowhead Pharmaceuticals?

How do I contact Arrowhead Pharmaceuticals' investor relations team?